

**A V E X A**

Avexa Limited  
ABN 53 108 150 750  
576 Swan Street Richmond  
Victoria Australia 3121

Telephone 61 3 9208 4300  
Facsimile 61 3 9208 4004  
Website [www.avexa.com.au](http://www.avexa.com.au)

## **AVEXA APPLICATION FOR QUOTATION OF PLACEMENT SECURITIES**

16 February 2005

Anti-infectives drug development company Avexa Ltd (ASX: AVX) today announced it has raised \$2.4 million through a placement of 12 million ordinary shares to institutions and sophisticated retail investors at \$0.20 per share. This represents nearly 15% of Avexa's current issued capital and does not require shareholder approval.

The primary purpose of the issue is to develop the compound AVX754 in-licensed from Shire Pharmaceuticals Group plc as a treatment of HIV and, in addition, to provide working capital for the company.

The company applies for quotation of these shares.

**Robyn M Fry**  
**Company Secretary**

### **About Avexa**

Avexa Limited is an ASX-listed, Melbourne-based biotechnology company with a focus on research and development of anti-infectives. The company is developing drugs for the treatment of infectious diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for its three key projects: antiviral drugs for HIV/AIDS and hepatitis, and an antibiotic alternative for antibiotic-resistant bacterial infections. This announcement has been prepared in line with the biotechnology industry reporting guidelines.